Beyond the intention-to-treat in comparative effectiveness research
- PMID: 21948059
- PMCID: PMC3731071
- DOI: 10.1177/1740774511420743
Beyond the intention-to-treat in comparative effectiveness research
Abstract
Background: The intention-to-treat comparison is the primary, if not the only, analytic approach of many randomized clinical trials.
Purpose: To review the shortcomings of intention-to-treat analyses, and of 'as treated' and 'per protocol' analyses as commonly implemented, with an emphasis on problems that are especially relevant for comparative effectiveness research.
Methods and results: In placebo-controlled randomized clinical trials, intention-to-treat analyses underestimate the treatment effect and are therefore nonconservative for both safety trials and noninferiority trials. In randomized clinical trials with an active comparator, intention-to-treat estimates can overestimate a treatment's effect in the presence of differential adherence. In either case, there is no guarantee that an intention-to-treat analysis estimates the clinical effectiveness of treatment. Inverse probability weighting, g-estimation, and instrumental variable estimation can reduce the bias introduced by nonadherence and loss to follow-up in 'as treated' and 'per protocol' analyses.
Limitations: These analyse require untestable assumptions, a dose-response model, and time-varying data on confounders and adherence.
Conclusions: We recommend that all randomized clinical trials with substantial lack of adherence or loss to follow-up are analyzed using different methods. These include an intention-to-treat analysis to estimate the effect of assigned treatment and 'as treated' and 'per protocol' analyses to estimate the effect of treatment after appropriate adjustment via inverse probability weighting or g-estimation.
Figures
Similar articles
-
Adjusting for adherence in randomized trials when adherence is measured as a continuous variable: An application to the Lipid Research Clinics Coronary Primary Prevention Trial.Clin Trials. 2020 Oct;17(5):570-575. doi: 10.1177/1740774520920893. Epub 2020 May 15. Clin Trials. 2020. PMID: 32414298
-
Interval-cohort designs and bias in the estimation of per-protocol effects: a simulation study.Trials. 2019 Sep 5;20(1):552. doi: 10.1186/s13063-019-3577-z. Trials. 2019. PMID: 31488202 Free PMC article.
-
Beyond intention to treat: what is the right question?Clin Trials. 2014 Feb;11(1):28-37. doi: 10.1177/1740774513504151. Epub 2013 Oct 3. Clin Trials. 2014. PMID: 24096636 Review.
-
Intention to treat and per protocol analyses: differences and similarities.J Clin Epidemiol. 2024 Sep;173:111457. doi: 10.1016/j.jclinepi.2024.111457. Epub 2024 Jul 6. J Clin Epidemiol. 2024. PMID: 38977160 Review.
-
Adherence adjustment in the Coronary Drug Project: A call for better per-protocol effect estimates in randomized trials.Clin Trials. 2016 Aug;13(4):372-8. doi: 10.1177/1740774516634335. Epub 2016 Mar 7. Clin Trials. 2016. PMID: 26951361 Free PMC article.
Cited by
-
Risk of suicide in patients with atrial fibrillation receiving different oral anticoagulants: a nationwide analysis using target trial emulation framework.BMC Med. 2024 Oct 11;22(1):451. doi: 10.1186/s12916-024-03645-z. BMC Med. 2024. PMID: 39394165 Free PMC article.
-
Artificial-Intelligence Cloud-Based Platform to Support Shared Decision-Making in the Locoregional Treatment of Breast Cancer: Protocol for a Multidimensional Evaluation Embedded in the CINDERELLA Clinical Trial.Pharmacoecon Open. 2024 Nov;8(6):945-959. doi: 10.1007/s41669-024-00519-1. Epub 2024 Sep 12. Pharmacoecon Open. 2024. PMID: 39264499 Free PMC article.
-
Adverse cardiovascular and kidney outcomes in people with SARS-CoV-2 treated with SGLT2 inhibitors.Commun Med (Lond). 2024 Sep 11;4(1):179. doi: 10.1038/s43856-024-00599-4. Commun Med (Lond). 2024. PMID: 39261630 Free PMC article.
-
User engagement in clinical trials of digital mental health interventions: a systematic review.BMC Med Res Methodol. 2024 Aug 24;24(1):184. doi: 10.1186/s12874-024-02308-0. BMC Med Res Methodol. 2024. PMID: 39182064 Free PMC article.
-
Common mistakes in biostatistics.Clin Kidney J. 2024 Jun 26;17(7):sfae197. doi: 10.1093/ckj/sfae197. eCollection 2024 Jul. Clin Kidney J. 2024. PMID: 39165900 Free PMC article. Review.
References
-
- Luce BR, Kramer JM, Goodman SN, Connor JT, Tunis S, Whicher D, Schwartz JS. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med. 2009;151:206–209. - PubMed
-
- Food and Drug Administration. International Conference on Harmonisation; Guidance on Statistical Principles for Clinical Trials. Federal Register. 1998;63:49583–49598. - PubMed
-
- Rosenberger WF, Lachin JM. Randomization in Clinical Trials: Theory and Practice. New York, NY: Wiley-Interscience; 2002.
-
- Piantadosi S. Clinical Trials: A Methodologic Perspective. 2nd edition. Hoboken, NY: Wiley-Interscience; 2005.
-
- Sheiner LB, Rubin DB. Intention-to-treat analysis and the goals of clinical trials. Clin Pharmacol Ther. 1995;57:6–15. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
